News | Contrast Media | August 17, 2023

Study investigated impact of radiographic media contrast shortage on stroke patient scan data 

Study investigated impact of radiographic media contrast shortage on stroke patient scan data

A study investigated impact of radiographic media contrast shortage on stroke patient scan data. Getty Images 


August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that discovered last year’s iodinated media contrast dye shortage affected the assessment of stroke patients at hospitals across the country. Injecting or drinking the media contrast helps doctors see blood vessels and organs more clearly in an x-ray or a computed tomography (CT) scan. 

Two specialized CT scans, CT angiographs (CTA) and CT perfusion (CTP) use the dye to check blood flow and the health of blood vessels. According to the study, the number of CTA and CTP scans across the country decreased during the shortage, which lasted from mid-April to early June of 2022. CTA scans decreased by around 10%, and CTP scans decreased by 26%. 

“The reduction was smaller than expected because there are other manufacturers of contrast media in the United States,” Qureshi said. “The reduction in CTPs was much greater and can be explained by how neurointerventionalists and strokephysicians use these tests. A CTA is important to identify if there is any blockage in the brain blood vessels that can be treated by clot removal. CTPs help identify whether there is salvageable brain tissue.” 

The shortage occurred after a COVID-19 outbreak forced a General Electric production facility in Shanghai, China to lockdown. As a result, GE Healthcare announced they would ration orders of the dye to medical facilities. While there were other suppliers worldwide, none could compensate for the drop in supply. 

Qureshi said these findings highlight the need to reduce the reliance on radiographic media contrast imaging without compromising patient outcomes. Some suggested methods include doing more magnetic resonance imaging (MRI) scans and reducing the amount of dye used per patient. 

“Another aspect that needs to be considered is whether comprehensive stroke centers should be prioritized during a contrast media shortage, since they are seeing a larger number of stroke patients and are also selecting patients for clot removal treatments,” Qureshi said. 

The research team analyzed data of more than 70,000 patients associated with Viz.ai, a commercial neuroimaging database. The data was anonymized and compliant with HIPAA guidelines and did not compromise any patient health information. 

Effect of Radiographic Contrast Media Shortage on Stroke Evaluation in the United States was published July 2023 in the American Journal of Neuroradiology

For more information: https://missouri.edu/ 


Related Content

News | Lung Imaging

May 24, 2024 — Smokers who have small abnormalities on their CT scans that grow over time have a greater likelihood of ...

Time May 24, 2024
arrow
News | Radiology Business

May 22, 2024 — Medtronic has announced new preliminary data from the VERITAS clinical study using its ILLUMISITE ...

Time May 22, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Artificial Intelligence

May 15, 2024 — Heart disease is the leading cause of mortality in the U.S., accounting for one out of every five deaths ...

Time May 15, 2024
arrow
News | Pediatric Imaging

May 15, 2024 — Transfer learning (TL) models trained on heterogeneous public datasets and fine-tuned using institutional ...

Time May 15, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
arrow
Subscribe Now